Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma

Overview

Journal J Thorac Oncol

Publisher Elsevier

Specialties Oncology
Pulmonary Medicine

Date 2016 Feb 5

PMID 26845118

Citations 34

Authors

Andrea Bille

Lee M Krug

Kaitlin M Woo

Valerie W Rusch

Marjorie G Zauderer

Affiliations

Soon will be listed here.

Abstract

Introduction: Previous prognostic scoring systems for malignant pleural mesothelioma (MPM) included patients managed surgically and predated the use of pemetrexed. We analyzed prognostic factors in a contemporary cohort of patients with unresectable MPM who received pemetrexed-based chemotherapy.

Methods: This single-institution analysis included patients with MPM who were managed nonsurgically from 2000 to 2013. Variables correlated with overall survival (OS) included sex, performance status (PS), asbestos exposure, tumor laterality, histology, clinical stage, initial positron emission tomography maximum standardized uptake value, hemoglobin level, platelet count, lymphocyte count, white cell and neutrophil counts, treatment type, and clinical benefit from treatment. OS was analyzed by the Kaplan-Meier method, and significance (p < 0.05) of prognostic factors was analyzed by the log-rank test and Cox regression.

Results: A total of 191 patients met the study criteria: median age 71 years (range 46-90), 147 men (77%), 128 epithelioid tumors (67%), and 157 cases of stage III or IV MPM (82%). Median OS for all patients was 13.4 months. According to a univariate analysis, histology (p < 0.001), platelet count (< or = 450,000 versus >450,000, p < 0.001), initial PS (0-1 versus > or = 2), maximum standardized uptake value (< or = 8.1 versus >8.1, p = 0.037), and lymphocyte counts (p = 0.019) were associated with OS. According to a multivariable analysis, only histology, platelet count, and PS were independent prognostic factors. Epithelioid histology, PS, and elevated lymphocyte count at diagnosis were significantly associated with clinical benefit from first-line chemotherapy.

Conclusions: Our results confirm the significance of elements of the Cancer and Leukemia Group B and European Organisation for Research and Treatment of Cancer prognostic scoring systems, identify factors associated with clinical benefit from chemotherapy, and emphasize the impact of histology and clinical benefit of chemotherapy on outcomes.

Citing Articles

Diagnosis of Pleural Mesothelioma: Is Everything Solved at the Present Time?.

Roca E, Aujayeb A, Astoul P Curr Oncol. 2024; 31(9):4968-4983.

PMID: 39329996 PMC: 11430569. DOI: 10.3390/curroncol31090368.

Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.

Van den Bossche J, De Laere M, Deschepper K, Germonpre P, Valcke Y, Lamont J PLoS One. 2024; 19(7):e0307204.

PMID: 39008481 PMC: 11249236. DOI: 10.1371/journal.pone.0307204.

Editorial: A year in review: discussions in pulmonary medicine.

Wang Y, Mirsaeidi M, Bai C, Yang D Front Med (Lausanne). 2024; 11:1434562.

PMID: 38882663 PMC: 11176607. DOI: 10.3389/fmed.2024.1434562.

Validation of Inflammatory Prognostic Biomarkers in Pleural Mesothelioma.

Iser S, Hintermair S, Varga A, Celik A, Sayan M, Kankoc A Cancers (Basel). 2024; 16(1).

PMID: 38201520 PMC: 10778470. DOI: 10.3390/cancers16010093.

Predicting survival for patients with mesothelioma: development of the PLACE prognostic model.

Zhang Y, Li N, Li R, Gu Y, Liu X, Zhang S BMC Cancer. 2023; 23(1):698.

PMID: 37495975 PMC: 10369846. DOI: 10.1186/s12885-023-11180-y.

References

Pass H, Giroux D, Kennedy C, Ruffini E, Cangir A, Rice D . Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee. J Thorac Oncol. 2014; 9(6):856-64. PMC: 4132031. DOI: 10.1097/JTO.0000000000000181. View

Zellos L, Christiani D . Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac Surg Clin. 2004; 14(4):469-77, viii. DOI: 10.1016/j.thorsurg.2004.06.011. View

Erasmus J, Truong M, Smythe W, Munden R, Marom E, Rice D . Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J Thorac Cardiovasc Surg. 2005; 129(6):1364-70. DOI: 10.1016/j.jtcvs.2004.10.034. View

Ceresoli G, Grosso F, Zucali P, Mencoboni M, Pasello G, Ripa C . Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey. Br J Cancer. 2014; 111(2):220-6. PMC: 4102949. DOI: 10.1038/bjc.2014.312. View

Flores R, Akhurst T, Gonen M, Larson S, Rusch V . Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2003; 126(1):11-6. DOI: 10.1016/s0022-5223(03)00207-1. View

Davidson B . Prognostic factors in malignant pleural mesothelioma. Hum Pathol. 2015; 46(6):789-804. DOI: 10.1016/j.humpath.2015.02.006. View

Herndon J, Green M, Chahinian A, Corson J, Suzuki Y, Vogelzang N . Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998; 113(3):723-31. DOI: 10.1378/chest.113.3.723. View

Nowak A, Armato 3rd S, Ceresoli G, Yildirim H, Francis R . Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group. Lung Cancer. 2010; 70(1):1-6. DOI: 10.1016/j.lungcan.2010.05.016. View

Kadota K, Kachala S, Nitadori J, Suzuki K, Dunphy M, Sima C . High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology. J Thorac Oncol. 2012; 7(7):1192-7. PMC: 3691682. DOI: 10.1097/JTO.0b013e3182519d96. View

10.

Rusch V, Giroux D, Kennedy C, Ruffini E, Cangir A, Rice D . Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012; 7(11):1631-9. DOI: 10.1097/JTO.0b013e31826915f1. View

11.

Kataoka Y, Yamamoto Y, Otsuki T, Shinomiya M, Terada T, Fukuma S . A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index. Jpn J Clin Oncol. 2015; 45(6):562-8. DOI: 10.1093/jjco/hyv039. View

12.

Zauderer M, Kass S, Woo K, Sima C, Ginsberg M, Krug L . Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer. 2014; 84(3):271-4. PMC: 4343315. DOI: 10.1016/j.lungcan.2014.03.006. View

13.

Curran D, Sahmoud T, Therasse P, Van Meerbeeck J, Postmus P, Giaccone G . Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998; 16(1):145-52. DOI: 10.1200/JCO.1998.16.1.145. View

14.

Vogelzang N, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P . Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21(14):2636-44. DOI: 10.1200/JCO.2003.11.136. View